Table 2.
Comparison of the Baseline Characteristics of Patients with Compensated Cirrhosis who Received Transarterial Chemoembolization (TACE) versus Best Supportive Care (BSC)
| Characteristics | BSC (n=18) | TACE (n=61) | P value |
|---|---|---|---|
| Male sex | 13 (72.2%) | 45 (73.8%) | 1 |
| Age (years): mean ± SD | 61.3 ± 10.9 | 59.0 ± 11.9 | 0.472 |
| BMI (kg/m2): mean ± SD | 21.2 ± 4.1 | 23.3 ± 4.5 | 0.081 |
| Etiology of chronic liver disease | |||
| Hepatitis B infection | 9 (50.0%) | 28 (45.9%) | 0.759 |
| Hepatitis C infection | 1 (5.6%) | 15 (24.6%) | 0.101 |
| Alcohol-related liver disease | 4 (22.2%) | 17 (27.9%) | 0.767 |
| Portal hypertension | 5 (27.8%) | 39 (63.9%) | 0.001 |
| Laboratory data | |||
| Hemoglobin (g/dL): mean ± SD | 10.7 ± 4.4 | 12.2 ±1.9 | 0.165 |
| Platelet median (x103/mL): median (IQR) | 216 (138 to 311) | 129 (96 to 254) | 0.143 |
| Serum creatinine (mg/dL): median (IQR) | 0.93 ± 0.31 | 0.89 ± 0.24 | 0.547 |
| Serum Albumin (g/dL): mean ± SD | 3.5 ± 0.5 | 3.8 ± 0.5 | 0.049 |
| Total bilirubin (mg/dL): median (IQR) | 0.9 (0.7 to 1.3) | 1.0 (0.6 to 1.4) | 0.856 |
| INR: mean ± SD | 1.0 ± 0.5 | 1.1 ± 0.1 | 0.136 |
| Alpha-fetoprotein (IU/mL): median (IQR) | 1,610.3 (6.7 to 18,099.4) | 29.6 (7.8 to 1,258) | 0.254 |
| Alpha-fetoprotein > 200 (IU/mL) | 11 (61.1%) | 23 (37.7%) | 0.078 |
| ECOG score | 0.03 | ||
| 0 | 10 (55.6%) | 50 (82.0%) | |
| >0 | 8 (44.4%) | 11 (18.0%) | |
| Multinodular | 15 (83.3%) | 41 (67.2%) | 0.186 |
| Tumor > 5 cm | 11 (61.1%) | 28 (45.9%) | 0.257 |
| Median longest tumor size (cm): median (IQR) | 7.0 (4.0 to 12.8) | 4.9 (3.5 to 9.5) | 0.179 |
Data are expressed as number (%) unless otherwise specified. BMI, body mass index; SD, standard deviation; INR, international normalized ratio; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group